FIRVANQ

Serial Number 87451656
Registration 5525903
702

Registration Progress

Application Filed
May 16, 2017
Under Examination
Dec 12, 2017
Approved for Publication
Oct 17, 2017
Published for Opposition
Oct 17, 2017
Registered
Jul 24, 2018

Trademark Image

FIRVANQ

Basic Information

Serial Number
87451656
Registration Number
5525903
Filing Date
May 16, 2017
Registration Date
July 24, 2018
Published for Opposition
October 17, 2017
Drawing Code
4

Status Summary

Current Status
Active
Status Code
702
Status Date
Sep 12, 2024
Registration
Registered
Classes
005

Rights Holder

AZURITY PHARMACEUTICALS, INC.

03
Address
8 CABOT ROAD, SUITE 2000
WOBURN, MA 01801

Ownership History

CutisPharma, Inc.

Original Applicant
03
Wilmington, MA

CutisPharma, Inc.

Owner at Publication
03
Wilmington, MA

CutisPharma, Inc.

Original Registrant
03
Woburn, MA

AZURITY PHARMACEUTICALS, INC.

New Owner After Registration #1
03
WOBURN, MA

Legal Representation

Attorney
Douglas R. Wolf

USPTO Deadlines

Next Deadline
945 days remaining
Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20180724)
Due Date
July 24, 2028
Grace Period Ends
January 24, 2029

Application History

31 events
Date Code Type Description Documents
Mar 19, 2025 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Sep 12, 2024 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Sep 12, 2024 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Sep 12, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Mar 4, 2024 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Jul 24, 2023 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Apr 29, 2020 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
May 23, 2019 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
May 23, 2019 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Mar 26, 2019 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Mar 26, 2019 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jul 24, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 20, 2018 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jun 19, 2018 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
May 31, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 8, 2018 IUAF S USE AMENDMENT FILED Loading...
May 31, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 8, 2018 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Dec 12, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 17, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 17, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 27, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 6, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 2, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 1, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 1, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 15, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 15, 2017 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 15, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 15, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
May 22, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 005
antibiotics; pharmaceutical preparations, namely, vancomycin for the treatment of colitis and gastrointestinal disorders in oral solution form, powder form and diluent form; pharmaceutical preparations, namely, vancomycin for the treatment of clostridium difficile and staphylococcus aureus colitis in oral solution form, powder form and diluent form
First Use Anywhere: Apr 2, 2018
First Use in Commerce: Apr 2, 2018

Classification

International Classes
005